SAN FRANCISCO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- On August 5, 2025, investors in Hims & Hers Health (NYSE: HIMS) declined almost 11% in another sell-off after the company disclosed that it would lower revenue recognized per customer specific to its so-called personalized GLP-1 component, a medication the company compounds to treat weight loss. This disclosure comes as the company previously experienced a sell-off in its shares which triggered a securities class action lawsuit tied to a cancelled collaboration with pharmaceutical giant Novo Nordisk to expand the availability of one of two FDA-approved weight loss drugs -- Wegovy® -- to …

Markel Group is set to grow on rate increases, strategic buyouts, new business volume, solid capital position and prudent capital deployment.

Expectations for September Rate Cut Soar.

SPLG surges to a 52-week high, lifted by record S&P 500 levels, rate-cut optimism, and AI-driven market momentum.

CCI's 16.3% six-month climb is driven by 5G growth, tower expansion and stable revenues from long-term leases.

Salesforce's ADAM framework, which includes Agents, Data, Apps, and Metadata, aims to power safe, scalable AI agents and fuel the company's next growth phase.

ROSELAND, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, August 15th, 2025, to discuss the company's financial results for the second quarter ended June 30, 2025, as well as the company's corporate progress and other developments.

Key Points in This Article: CoreWeave's (CRWV) Q2 revenue of $1.21 billion surpassed estimates, driven by AI demand.

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

AST SpaceMobile continues to miss satellite launch targets, delaying commercial service and raising doubts about execution. Competitive threats from Starlink and T-Mobile have intensified, making ASTS's late entry and value proposition less compelling. Revenue projections appear overly optimistic given persistent delays, questionable demand, and reliance on MNO partnerships for growth.

Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Brian C. DeSchuytner - Senior VP, CFO & COO Jason Fredette - Senior Vice President of Investor Relations & Corporate Communications Martin H.

HudBay Minerals Inc. (TSX:HBM) shares surged after the miner announced a $600 million strategic investment from Mitsubishi for a 30% joint venture interest in the Copper World project in Arizona. Announced alongside its Q2 earnings, the deal includes an initial cash investment of $420 million, with $180 million to follow within 18 months.

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Pinterest's solid Q2 revenues and AI-driven ad tools fuel growth, but rising costs and tough competition weigh on margins.

Taiwan Semiconductor pushes nanosheet tech with N2, N2P, A16, and A14 nodes, targeting speed, power, and density gains to extend chip leadership.

Opening Bid anchor Brian Sozzi breaks down the latest market news for August 13, 2025. F/m Investments CEI & CIO Alex Morris joins our panel to explain why he believes the market rally will continue, his strategy for investing, Fed rate cuts, and inflation.

QuantumScape remains a speculative play, but its advancements on milestones and robust cash reserves support my continued buy rating. Successful integration of next-gen Cobra separator boosts production efficiency, positioning QS for future solid-state battery demand and OEM interest. Strong financials, asset-light model, and Volkswagen partnership ensure sustainability, with a cash runway of up to 32 months including new funding.

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of The J.M. Smucker Company (“Smucker” or the “Company”) (NYSE: SJM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Dietrich John Pauls - President, CEO & Director Julie Krop - Chief Medical Officer Scott Kellen - CFO & Corporate Secretary Conference Call Participants Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Q2 2025 Earnings Conference Call. An audio recording of this webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the …

Heavy spending on payments, shipping and credit expansion is fueling MELI's market reach, yet margins reflect the strain of rapid growth plans.